Levemir Related Published Studies
Well-designed clinical trials related to Levemir (Insulin Detemir Subcutaneous)
Short-term effects of the long-acting insulin analog detemir and human insulin on plasma levels of insulin-like growth factor-I and its binding proteins in humans. [2009.08]
Study rationale and design of the CIMT trial: the Copenhagen Insulin and Metformin Therapy trial. [2009.04]
Comparison of Inpatient Insulin Regimens with Detemir plus Aspart Versus Neutral Protamine Hagedorn plus Regular in Medical Patients with Type 2 Diabetes. [2009.02]
Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial. [2009.01]
Insulin detemir is characterized by a more reproducible pharmacokinetic profile than insulin glargine in children and adolescents with type 1 diabetes: results from a randomized, double-blind, controlled trial. [2008.12]
Insulin detemir is characterized by a more reproducible pharmacokinetic profile than insulin glargine in children and adolescents with type 1 diabetes: results from a randomized, double-blind, controlled trial. [2008.08.27]
Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial. [2008.08]
Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia. [2008.08]
Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial. [2008.07.17]
Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial. [2008.04]
A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. [2008.03]
Different brain responses to hypoglycemia induced by equipotent doses of the long-acting insulin analog detemir and human regular insulin in humans. [2008.03]
Improving glycemic control with insulin detemir using the 303 Algorithm in insulin naive patients with type 2 diabetes: a subgroup analysis of the US PREDICTIVE 303 study. [2008.01]
Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. [2007.10.25]
Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study. [2007.10]
Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapy. [2007.06]
Prandial premixed insulin analogue regimens versus Basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison. [2007.06]
Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. [2007.05]
Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes. [2007.01]
Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index. [2007]
Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison. [2007]
Time-action profile of insulin detemir and NPH insulin in patients with type 2 diabetes from different ethnic groups. [2006.09]
Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetes. [2006.07]
A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. [2006.06]
Comparison of three multiple injection regimens for Type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin. [2005.07]
A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. [2005.05]
Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. [2005.01]
Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. [2005.01]
Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. [2004.11]
The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes. [2004.10]
Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. [2004.06]
Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen. [2004.05]
Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. [2004.05]
Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. [2004.04]
Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes. [2003.11]
Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. [2003.03]
Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy. [2001.02]
Pharmacokinetic and pharmacodynamic properties of long-acting insulin analogue NN304 in comparison to NPH insulin in humans. [2000]
Other research related to Levemir (Insulin Detemir Subcutaneous)
Pharmacokinetics and pharmacodynamics of insulin lispro protamine suspension compared with insulin glargine and insulin detemir in type 2 diabetes. [2009.11]
Observational, open-label study of type 1 and type 2 diabetes patients switching from human insulin to insulin analogue basal-bolus regimens: insights from the PREDICTIVE study. [2009.11]
Differential effects of insulin detemir and neutral protamine Hagedorn (NPH) insulin on hepatic glucose production and peripheral glucose uptake during hypoglycaemia in type 1 diabetes. [2009.11]
Insulin detemir causes increased symptom awareness during hypoglycaemia compared to human insulin. [2009.11]
No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis. [2009.10.17]
Insulin analogs and pregnancy: an update. [2009.09]
Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes. [2009.09]
Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study. [2009.06]
Preoperative hypoglycemia in a patient receiving insulin detemir. [2009.06]
Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis. [2009.05]
Waist circumference reduction after insulin detemir therapy in type 2 diabetes patients previously treated with NPH. [2009.05]
Higher dose requirements with insulin detemir in type 2 diabetes--three cases and a review of the literature. [2009.05]
Once-daily insulin detemir in a cohort of insulin-naive patients with type 2 diabetes: a sub-analysis from the PREDICTIVE study. [2009.04]
[Insulin detemir in the predictive study: results in patients with type 1 diabetes in the Belgian cohort] [2009.03]
A comparison of insulin use, glycemic control, and health care costs with insulin detemir and insulin glargine in insulin-naive patients with type 2 diabetes. [2009.03]
Switching patients from insulin glargine-based basal-bolus regimens to a once daily insulin detemir-based basal-bolus regimen: results from a subgroup of the PREDICTIVE study. [2009.03]
Cost-effectiveness of insulin analogues for diabetes mellitus. [2009.02.17]
Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. [2009.02.17]
Basal-bolus therapy with insulin detemir using the 303 algorithm in the US PREDICTIVE 303 trial. [2009.02]
Oral glutamine dipeptide prevents against prolonged hypoglycemia induced by Detemir insulin in rats. [2009.02]
Once-daily insulin detemir is comparable to once-daily insulin glargine in providing glycaemic control over 24 h in patients with type 2 diabetes: a double-blind, randomized, crossover study. [2009.01]
Comparison of once- versus twice-daily administration of insulin detemir, used with mealtime insulin aspart, in basal-bolus therapy for type 1 diabetes: assessment of detemir administration in a progressive treat-to-target trial (ADAPT). [2009.01]
Insulin detemir in routine clinical practice: a 26-week follow-up in type 1 diabetic patients from the Belgian PREDICTIVE Cohort. [2009.01]
Insulin analog therapy: improving the match with physiologic insulin secretion. [2009.01]
The role of insulin detemir in overweight type 2 diabetes management. [2009]
Cost-effectiveness of insulin detemir compared with neutral protamine Hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in five European countries. [2009]
Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia. [2009]
The role of new basal insulin analogues in the initiation and optimisation of insulin therapy in type 2 diabetes. [2008.12]
Switching from NPH insulin to once-daily insulin detemir in basal-bolus-treated patients with diabetes mellitus: data from the European cohort of the PREDICTIVE study. [2008.12]
A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. [2008.11]
A comparison of once- versus twice-daily administration of insulin detemir, used with mealtime insulin aspart, in basal-bolus therapy for type 1 diabetes: the ADAPTTM Study. [2008.10.22]
Beyond the era of NPH insulin--long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application. [2008.10]
Safety, simplicity and convenience of a modified prefilled insulin pen. [2008.09]
Evaluation of the injection force dynamics of a modified prefilled insulin pen. [2008.09]
Insulin analogs: impact on treatment success, satisfaction, quality of life, and adherence. [2008.09]
Characteristics of signalling properties mediated by long-acting insulin analogue glargine and detemir in target cells of insulin. [2008.09]
Indirect Comparison of Once Daily Insulin Detemir and Glargine in Reducing Weight Gain and Hypoglycaemic Episodes when Administered in Addition to Conventional Oral Anti-Diabetic Therapy in Patients with Type-2 Diabetes. [2008.08.01]
An update on the use of insulin detemir, with a focus on type 2 diabetes (drug evaluation update). [2008.08]
Improved glycemic control and lower frequency of severe hypoglycemia with insulin detemir; long-term experience in 105 children and adolescents with type 1 diabetes. [2008.08]
Evaluating the cost-effectiveness of therapy conversion to insulin detemir in patients with type 2 diabetes in Germany: a modelling study of long-term clinical and cost outcomes. [2008.06]
[Health economic consequences of insulin analogues in the treatment of type 1 diabetes in Denmark] [2008.04.07]
Insulin detemir improves glycaemic control without weight gain in insulin-naive patients with type 2 diabetes: subgroup analysis from the PREDICTIVE study. [2008.04]
A case of lipoatrophy with insulin detemir. [2008.04]
Role of insulin signaling in maintaining energy homeostasis. [2008.04]
Safety and efficacy of insulin detemir basal-bolus therapy in type 1 diabetes patients: 14-week data from the European cohort of the PREDICTIVE study. [2008.02]
Insulin analogues: action profiles beyond glycaemic control. [2008.02]
Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal-only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia: 14-week follow-up data from PREDICTIVE. [2008.01]
[Long-term improvement of fasting glycaemia after switching basal insulin from NPH to determir in children with type 1 diabetes: a 1-year multicentre study] [2008]
Indirect comparison of once daily insulin detemir and glargine in reducing weight gain and hypoglycaemic episodes when administered in addition to conventional oral anti-diabetic therapy in patients with type-2 diabetes. [2008]
Insulin analog preparations and their use in children and adolescents with type 1 diabetes mellitus. [2008]
Deleterious outcomes after abrupt transition from insulin glargine to insulin detemir in patients with type 1 diabetes mellitus. [2008]
New insulin analogues and routes of delivery: pharmacodynamic and clinical considerations. [2008]
Prevailing therapeutic regimes and predictive factors for prandial insulin substitution in 26 687 children and adolescents with Type 1 diabetes in Germany and Austria. [2007.12]
Cerebrocortical beta activity in overweight humans responds to insulin detemir. [2007.11.21]
The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes - results of the randomized, controlled PREDICTIVEtrade mark 303 study. [2007.11]
Lower risk of hypoglycemia with insulin detemir than with neutral protamine hagedorn insulin in older persons with type 2 diabetes: a pooled analysis of phase III trials. [2007.11]
Insulin-associated weight gain in diabetes--causes, effects and coping strategies. [2007.11]
Which basal insulin should be used in patients with type 2 diabetes mellitus? [2007.10]
Optimizing insulin use in type 2 diabetes: role of basal and prandial insulin in long-term care facilities. [2007.10]
Insulin detemir: a new option for the treatment of diabetes. [2007.10]
Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes. [2007.09.21]
Refining basal insulin therapy: what have we learned in the age of analogues? [2007.09]
Insulin glulisine: a faster onset of action compared with insulin lispro. [2007.09]
|
